Non-peptide Keap1-Nrf2 Inhibitors for Safe Antioxidant Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule Nrf2/ARE inducers are chemically reactive, raising safety concerns for long-term use due to potential toxicity, and direct disruption of Keap1-Nrf2 protein-protein interaction with peptides is challenging due to poor membrane permeability and susceptibility to proteolysis.
Innovation Solution
Development of non-peptide small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction to modulate inflammatory processes, using high throughput screening and structure-based drug design to identify potent compounds that can effectively block the interaction between Keap1 and Nrf2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically reactive compounds (e.g., sulforaphane, curcumin, oltipraz) are used to induce Nrf2/ARE, then antioxidant response is activated, but safety concerns arise due to potential toxicity from long-term use
Solution Approach 1:
The patent uses peptides as intermediary molecules that bind to Keap1 and disrupt its interaction with Nrf2, thereby activating the antioxidant response without requiring chemically reactive compounds. The peptide acts as a mediator that achieves the desired biological effect (Nrf2 activation) through a safer mechanism (protein-protein interaction disruption rather than covalent modification), resolving the contradiction between effectiveness and safety for long-term use.
2Manufacturing precision
If peptides are used to disrupt Keap1-Nrf2 interaction, then direct inhibition is achieved, but poor membrane permeability and susceptibility to proteolysis limit their effectiveness
Solution Approach 1:
The patent modifies the physical and chemical parameters of the peptide inhibitors by conjugating them with cell-penetrating peptides (CPPs) such as TAT, penetratin, or transportan. This parameter change enhances membrane permeability and proteolytic stability while maintaining the ability to disrupt Keap1-Nrf2 interaction, thereby resolving the contradiction between direct inhibition capability and ease of operation in biological systems.
3Productivity
If indirect irreversible inhibitors (chemically reactive compounds) are used, then Keap1-Nrf2 complex formation is disrupted, but concerns about long-term toxicity prevent further development
Solution Approach 1:
The patent employs peptides as intermediaries that achieve Nrf2 activation through reversible disruption of the Keap1-Nrf2 complex rather than irreversible chemical modification. This intermediary approach maintains high productivity in activating antioxidant genes while improving long-term safety by avoiding the toxicological concerns associated with chemically reactive compounds, thus resolving the contradiction between effectiveness and reliability.
Data Source
AI summary
A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.